We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

95 hedge funds and large institutions have $248M invested in Dianthus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

767% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 3

42% more capital invested

Capital invested by funds: $174M → $248M (+$73.3M)

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

32% more funds holding

Funds holding: 72 → 95 (+23)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.02% less ownership

Funds ownership: 4.41% → 4.39% (-0.02%)

97% less call options, than puts

Call options by funds: $4K | Put options by funds: $117K

Holders
95
Holders Change
+23
Holders Change %
+31.94%
% of All Funds
1.95%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
31
Reduced
23
Closed
3
Calls
$4K
Puts
$117K
Net Calls
-$113K
Net Calls Change
-$113K

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$5.28M
2
EAM
Eventide Asset Management
Massachusetts
+$5.02M
3
AG
Artal Group
Luxembourg
+$3.96M
4
EC
EcoR1 Capital
California
+$3.96M
5
CH
CVI Holdings
Delaware
+$3.65M

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$3.38M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$581K
3
MWNA
Marshall Wace North America
New York
-$435K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$358K
5
Citadel Advisors
Citadel Advisors
Florida
-$200K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP IV
Massachusetts
$60.1M – – –
GGHC
2
Gilder Gagnon Howe & Co
New York
$32.5M +$2.41M +17,119 +7%
CC
3
Casdin Capital
New York
$25.1M +$3.3M +23,437 +13%
AI
4
Alphabet Inc
California
$25.1M – – –
EAM
5
Eventide Asset Management
Massachusetts
$17.7M +$5.02M +35,625 +32%
BlackRock
6
BlackRock
New York
$12M -$170K -1,204 -1%
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.82M +$2.48M +17,608 +32%
Alkeon Capital Management
8
Alkeon Capital Management
New York
$4.51M – – –
UBS AM
9
UBS AM
Illinois
$4.51M +$5.28M +37,500 New
AG
10
Artal Group
Luxembourg
$3.38M +$3.96M +28,125 New
EC
11
EcoR1 Capital
California
$3.38M +$3.96M +28,125 New
CH
12
CVI Holdings
Delaware
$3.11M +$3.65M +25,880 New
State Street
13
State Street
Massachusetts
$2.72M +$71.6K +508 +2%
LM
14
Luminus Management
Texas
$2.7M +$3.16M +22,449 New
BL
15
Bleichroeder LP
New York
$2.64M +$881K +6,250 +40%
HMC
16
Harvard Management Company
Massachusetts
$2.5M – – –
Millennium Management
17
Millennium Management
New York
$2.1M +$396K +2,810 +19%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.1M +$78.2K +555 +3%
Northern Trust
19
Northern Trust
Illinois
$1.97M +$295K +2,091 +15%
PIM
20
Platinum Investment Management
Australia
$1.81M -$172K -1,218 -7%
Bessemer Group
21
Bessemer Group
New Jersey
$1.78M – – –
Principal Financial Group
22
Principal Financial Group
Iowa
$1.74M +$5.21K +37 +0.3%
Morgan Stanley
23
Morgan Stanley
New York
$1.61M +$1.87M +13,301 +12,668%
ACM
24
Asymmetry Capital Management
California
$1.58M +$1.86M +13,191 New
Renaissance Technologies
25
Renaissance Technologies
New York
$1.58M +$357K +2,535 +24%
1
2 3 4

DNTH Hedge Fund Activity: Q2 2020 in Review

95 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2020, worth a combined $248M — up 42% from $174M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new DNTH positions and 3 closed out — a net gain of 23 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was UBS AM, opening a new position worth an estimated $5.28M. The largest seller was Opaleye Management, cutting an estimated $3.38M.

  • 95 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2020, up from 72 in Q1 2020.
  • Funds reported $248M of Dianthus Therapeutics stock for Q2 2020, up 42% quarter-over-quarter.
  • 26 funds opened new Dianthus Therapeutics positions in Q2 2020 and 3 closed out, a net change of +23 holders.
  • The largest Dianthus Therapeutics buyer in Q2 2020 was UBS AM, an estimated $5.28M added.
  • The largest Dianthus Therapeutics seller in Q2 2020 was Opaleye Management, an estimated $3.38M sold.

Based on aggregated 13F filings for Q2 2020.